Looks like you’re on the UK site. Choose another location to see content specific to your location
Sanofi and Regeneron receive award for asthma therapy
Sanofi and Regeneron Pharmaceuticals have been presented with a research award from Scrip Intelligence for their work on the asthma therapy dupilumab.
The companies' phase IIa study of the investigational drug has earned the clinical advance of the year prize at the 2013 Scrip Awards after being selected by a 15-member panel of leading pharmaceutical industry executives, consultants and researchers.
Dupilumab is a fully-human monoclonal antibody in phase IIb clinical development for treatment of asthma, atopic dermatitis and nasal polyposis. It was created using Regeneron's VelocImmune gene modification technologies and is being co-developed with Sanofi.
Dr Elias Zerhouni, global research and development president at Sanofi, said: "On behalf of all of the men and women within our organisations working diligently to develop this investigational treatment, we are truly honoured by this award."
This comes after the two companies announced positive clinical trial data for sarilumab, their new therapy for rheumatoid arthritis, earlier this month.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard